Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines

Jun-Jun Wu; Wen-Hao Li; Pu-Guang Chen; Bo-Dou Zhang; Hong-Guo Hu; Qian-Qian Li; Lang Zhao; Yong-Xiang Chen; Yu-Fen Zhao; Yan-Mei Li

doi:10.1039/C8CC04860F

Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines†

Jun-Jun Wu,^a Wen-Hao Li,^a Pu-Guang Chen,^a Bo-Dou Zhang,^a Hong-Guo Hu,^a Qian-Qian Li,^a Lang Zhao,^a Yong-Xiang Chen,^a Yu-Fen Zhao^a and Yan-Mei Li

*^abc

Author affiliations

* Corresponding authors

^a Key Lab of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, P. R. China
E-mail: liym@mail.tsinghua.edu.cn
Fax: +86-10-62781695
Tel: +86-10-62796197

^b Beijing Institute for Brain Disorders, Beijing 100069, P. R. China

^c Center for Synthetic and Systems Biology, Tsinghua University, Beijing 100084, P. R. China

Abstract

Cyclic di-GMP (CDG) was applied to MUC1 glycopeptide-based cancer vaccines with physical mixing and built-in (at 2′-OH of CDG) strategies for activating the STING pathway. CDG in both strategies behaved as a potent immunostimulant and contributed to high titers of IgG antibodies and the expression of multiple cytokines.

Chemical Communications

Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines†

Abstract

Supplementary files

Article information

Download Citation

Permissions

Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines

Social activity

Search articles by author

Spotlight

Advertisements